The completion of the first procedure marks the beginning of a controlled US commercial release.
|Videos|November 9, 2021
Why future research must be conducted for prevention of LUTS and BPH
Author(s)Urology Times staff
Advertisement
In this video, Jordan J. Kramer, MD, discusses why the findings of the REDUCE trial warrant further research into the prevention of LUTS and BPH. Kramer is a PGY4 urology resident at Cedars Sinai Medical Center, Los Angeles, California.
Advertisement
Related to this article
Butterfly Medical has also submitted a premarket approval application to the FDA.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
Engy Habashy, MD, on the role of androgens in GSM management
4
ESMO 2026: Key presentations across genitourinary oncology
5